ANDREA THOMAS: Open Payments
NPI 1225183767 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,107 in 68 payments from 16 companies in 2025. Trend: 2023 $1,198 · 2024 $831 · 2025 $1,107
Food & beverage: $1,107
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $194 |
| ABBVIE INC. | 21 | $172 |
| Supernus Pharmaceuticals, Inc. | 9 | $152 |
| Neurocrine BioSciences, Inc. | 4 | $121 |
| Vanda Pharmaceuticals Inc. | 3 | $99 |
| Corium, LLC | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Alkermes, Inc. | 2 | $36 |
Products named: CAPLYTA, VRAYLAR, Qelbree, INGREZZA, FANAPT, Azstarys, REXULTI, UZEDY.
Industry payments across AL — which companies pay providers there.
